News

Press Releases

Asuragen Launches the QuantideX® NGS Pan Cancer Kit*, a Workflow Solution for Targeted Next-Generation Sequencing
Asuragen Announces Launch of Highly Sensitive CE-IVD BCR-ABL Assay at the European Hematology Association Annual Congress
Asuragen to present innovations in fragile X testing at upcoming American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
Asuragen to join leading UK cancer research consortium to develop miRNA based sequencing tests for early detection and screening of cancer
Asuragen Launches the QuantideX® qPCR DNA QC Assay to Improve the Accuracy of Next-Generation Sequencing
Asuragen to present at upcoming Association for Molecular Pathology Annual Meeting in National Harbor, MD
Asuragen’s Xpansion Interpreter® Test Study of 1,040 Transmissions of Fragile X Alleles Reveals Personalized Risks for Expansion from Parent to Child
Asuragen and Labceutics Report Results from Pan European Quality Assurance-Modeled Study on Standardization of BCR-ABL1 Monitoring for CML Patients
Asuragen Names Matthew McManus, M.D., Ph.D., President and CEO
Asuragen Receives New York State License for Molecular Genetic and Oncology Clinical Laboratory Testing

About

Back To
Top